BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2005

View Archived Issues

Neuroprotective effects of IBU-PO, a novel bifunctional NSAID-cholinesterase inhibitor

Read More

Glycine transport inhibitors modulate dopamine in vitro

Read More

In vitro and in vivo pharmacology of the novel iNOS inhibitor FR-260330

Read More

Cytotoxic effects of telomerase inhibition with BIBR-1532 in leukemia cells

Read More

MedImmune amends ex-U.S. RSV agreement with Abbott

Read More

Tercica submits NDA for Increlex

Read More

Elusys files IND to begin human safety studies of Anthim

Read More

New phase II study to test TB4 for epidermolysis bullosa

Read More

BioPro takes Asia-Pacific rights to Vantas

Read More

Debiopharm purchases outstanding shares of H3 Pharma

Read More

Ono updates progress of ONO-2506 and inlicensed Merck compounds

Read More

Hexvix approved in 26 European countries

Read More

Enrollment open in phase II study of PTK/ZK in NSCLC

Read More

New phase II study for NeuroVax

Read More

Bionomics completes acquisition of Neurofit

Read More

Geron and BRC create new company for telomerase activation therapies

Read More

Valeant completes Xcel acquisition

Read More

Pivotal trial begins for FK-228 for CTCL

Read More

Procyon Biopharma grants Medicorp rights to PSP94-based test kits

Read More

Phase II data support the use of SPP-301 in diabetic nephropathy

Read More

NRP-104 reported effective in the treatment of ADHD

Read More

ALVAC vCP1452 shows efficacy in preventing viral rebound in HIV-infected patients

Read More

MVA-nef induces a strong specific immune response in HIV-infected patients

Read More

S-236 cream effective in pruritis, xerosis and atopic dermatitis in humans

Read More

Topical compound containing MMP and PKC inhibitors improves skin hypersensitivity in humans

Read More

New title added to the Drug R&D Backgrounders topic list - Autism Spectrum Disorders

Read More

Controlled release formulations for antiinfective therapy claimed

Read More

Two series of serotonin reuptake inhibitors reported by Merck

Read More

Novel anti-hepatitis C virus (HCV) agents discovered at Enanta

Read More

Celltech discloses the development of novel p38 MAP kinases for rheumatoid arthritis

Read More

New immunoglobulin E (IgE) production inhibitors and their use disclosed by Celltech

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing